• Blog
  • Ocular Drug Delivery Technology Market Report

    Ocular Drug Delivery Technology Market Report

    Ocular Drug Delivery Technology Market Report
    Report code - SRHL306 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Global Ocular Drug Delivery Technology Market, Dynamics, and Market Analysis
    See more...

    Impact of COVID-19 on Ocular Drug Delivery Technology Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Ocular Drug Delivery Technology Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Global Ocular Drug Delivery Technology Market is expected to grow from USD xx million in 2020 to USD xx million by 2026 at a CAGR of over xx% during the forecast period.

    Figure: Global Ocular Drug Delivery Technology Market Size, 2020-2026 (USD Million)

    Ocular-Drug-Delivery-Technology-Market-Forecast

    Wish to get a free sample report? Click here.

    What is Ocular Drug Technology?

    Ocular drug delivery technology is used to treat ophthalmic diseases such as cataracts, diabetic retinopathy, and glaucoma among others. These drugs are primarily used in liquid form which includes suspensions, solutions, and emulsions. Ocular medicines are delivered to the eyes using methods including topical, ocular insert, iontophoresis, and intraocular implant among others.

    Key Players

    Key players operating in the global Ocular Drug Delivery Technology Market are-

    • Alimera Sciences, Inc. (The US),
    • Bausch Health Companies Inc. (The US),
    • Clearside Biomedical, Inc. (The US),
    • Taiwan Liposome Company, Ltd. (Taiwan),
    • Novartis International AG (Switzerland),
    • Pfizer Inc. (The US),
    • Envisia Therapeutics, Inc. (The US),
    • Graybug Vision Inc. (The US),
    • Allergan plc (The US), and
    • Ocular Therapeutix, Inc (The US).

    Market Dynamics

    The growth of the global ocular drug delivery technology market is primarily driven by increasing prevalence of ophthalmic disorders.

    • Expanding geriatric populace suffering from vision impairment is expected to propel the market growth at a significant rate during the review period. Increasing investment in R&D activities to develop new drugs is likely to add to the market growth substantially. The high demand for technologically advanced solutions is likely to create lucrative growth opportunities for the market players.           

    Segment Analysis

    End User Trends

    Based on end user, the market has been segmented into hospitals, ambulatory surgical centres, ophthalmic clinics and homecare settings.

    • The hospitals segment accounted for the largest market share in 2020.
    • The segment growth can be attributed to presence of skilled staff and proper healthcare infrastructure in the hospitals coupled with increased healthcare spending across the globe.

    Regional Trends

    Geographically, the market in North America accounted for the largest market share in 2020 and is expected to continue its dominance over the forecast period owing to the increasing incidence of eye disorders coupled with expanding geriatric populace.

    • Additionally, increasing spending in R&D activities in the healthcare sector is expected to contribute to the market growth significantly.
    • The market in Asia-Pacific is expected to register healthy CAGR during the review period on account of rising spending on healthcare.

    COVID-19 Impact on Global Ocular Drug Delivery Technology Market

    The covid-19 outbreak posed significant challenges to the health care system across geographies. It affected the growth of the ocular drug delivery technology market negatively as patients postponed their treatment due to a rapid surge in covid-19 cases across geographies. Also, supply chain disruptions due to the imposition of lockdown affected the market growth further. Due to a surge in covid-19 cases across geographies only essential services were allowed. People moved out of their houses only for essential services due to fear of coronavirus infection and thus, affected the market growth for a short period.

    Critical Questions Answered in the Report

    • What are the key trends in the global Ocular Drug Delivery Technology market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global Ocular Drug Delivery Technology market?
    • What are the key strategies adopted by the major vendors to lead in the global Ocular Drug Delivery Technology market?
    • What is the market share of the top vendors?

    Wish to know more about the study? Click here to get a free sample.

    Target Audience

    • Ocular drug delivery technology manufacturers
    • Ocular drug delivery technology suppliers
    • Ocular drug delivery technology distributors
    • Organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].

    Frequently Asked Questions (FAQs)

    Alimera Sciences, Inc. (The US), Bausch Health Companies Inc. (The US), Clearside Biomedical, Inc. (The US), Taiwan Liposome Company, Ltd. (Taiwan), Novartis International AG (Switzerland), Pfizer Inc. (The US), Envisia Therapeutics, Inc. (The US), Graybug Vision Inc. (The US), Allergan plc (The US) and Ocular Therapeutix, Inc (The US) are among the key players in the ocular drug delivery technology market.

    North America accounted for the largest share in the ocular drug delivery technology market in 2020.

    The hospitals segment accounted for the largest share in the ocular drug delivery technology market in 2020.

    Increasing prevalence of ophthalmic disorders, expanding geriatric populace suffering from vision impairment are the factors driving the growth of ocular drug delivery technology market.

    Ocular drug delivery technology manufacturers, Ocular drug delivery technology suppliers, Ocular drug delivery technology distributors, Organizations, Government bodies are the target audience in the ocular drug delivery technology market.

    •